Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan

Cancers

Volumn 4, Issue 1, 2012, Pages 165-183

  Nishikawa, Hiroki ^a   Osaki, Yukio ^a   Kita, Ryuichi ^a   Kimura, Toru ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Advanced hepatocellular carcinoma; Chemotherapy; Hepatic arterial infusion chemotherapy; Response rate; Sorafenib

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IA CALL; IODINATED POPPYSEED OIL; MIRIPLATIN; MITOMYCIN C; OXALIPLATIN; SORAFENIB; UNCLASSIFIED DRUG; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ADVANCED CANCER; ANOREXIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CARDIOTOXICITY; CHEMOEMBOLIZATION; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HUMAN; JAPAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY DYSFUNCTION; LIVER CELL CARCINOMA; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; RESPIRATORY TRACT TUMOR; REVIEW; SURVIVAL RATE; TUMOR THROMBUS; URINARY TRACT CANCER; UROGENITAL TRACT TUMOR;

EID: 84859082653     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers4010165     Document Type: Review

References (105)

1. Curley, S.A.; Izzo, F.; Ellis, L.M.; Nicolas Vauthey, J.; Vallone, P. Radiofrequency ablation of hepatocellular carcinoma in 110 patients with cirrhosis. Ann. Surg. 2000, 232, 1694-1702.
2. Allgaier, H.P.; Deibert, P.; Zuber, I.; Olschewski, M.; Blum, H.E. Percutaneous radiofrequencyinterstitial thermal ablation of small hepatocellular carcinoma. Lancet 1999, 353, 1676-1677.
3. Okuda, K. Hepatocellular carcinoma: Recent progress. Hepatology 1992, 15, 948-963.
4. Lencioni, R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010, 52, 762-773.
5. Lai, E.C.; Lau, W.Y. The continuing challenge of hepatic cancer in Asia. Surgeon 2005, 3, 210-215.
6. Lau, W.Y.; Leung, T.W.; Yu, S.C.; Ho, S.K. Percutaneous local ablative therapy for hepatocellular carcinoma: A review and look into the future. Ann. Surg. 2003, 237, 171-179.
7. Boucher, E.; Corbinais, S.; Brissot, P.; Boudjema, K.; Raoul, J.L. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother. Pharmacol. 2002, 50, 305-308.
8. Okusaka, T.; Ueno, H.; Ikeda, M. Chemotherapy for hepatocellular carcinoma [in Japanese]. Gan To Kagaku Ryoho 2004, 31, 2122-2128.
9. Yeo, W.; Mok, T.S.; Zee, B.; Leung, T.W.; Lai, P.B.; Lau, W.Y.; Koh, J.; Mo, F.K.; Yu, S.C.; Chan, A.T.; et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst. 2005, 97, 1532-1538.
10. Gish, R.G.; Porta, C.; Lazar, L.; Ruff, P.; Feld, R.; Croitoru, A.; Feun, L.; Jeziorski, K.; Leighton, J.; Gallo, J.; Kennealey, G.T. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J. Clin. Oncol. 2007, 25, 3069-3075.
11. Edeline, J.; Raoul, J.L.; Vauleon, E.; Guillygomac'h, A.; Boudjema, K.; Boucher, E. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study. World J. Gastroenterol. 2009, 15, 713-716.
12. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378-390.
13. Llovet, J.M.; Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37, 429-442.
14. Llovet, J.M.; Real, M.I.; Montaña, X.; Planas, R.; Coll, S.; Aponte, J.; Ayuso, C.; Sala, M.; Muchart, J.; Solà, R.; et al.; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002, 359, 1734-1739.
15. Nagai, H.; Sumino, Y. Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. Recent Pat. Anticancer Drug Discov. 2008, 3, 220-226.
16. Ishikawa, T.; Higuchi, K.; Kubota, T.; Seki, K.; Honma, T.; Yoshida, T.; Kamimura, T. Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/II hepatocellular carcinoma. Cancer 2011, 117, 4018-4025.
17. Ishikawa, T. Future perspectives on the treatment of hepatocellular carcinoma with cisplatin. World J. Hepatol. 2009, 1, 8-16.
18. Hirose, H.; Aoyama, M.; Oshima, K.; Udo, K.; Kobayashi, S.; Adachi, N.; Nonaka, T.; Yamada, T. Chemotherapy of hepatocellular carcinoma-With special reference to one-shot intra-arterial infusion of a high dose of adriamycin (in Japanese). Gan To Kagaku Ryoho 1982, 9, 2216-2221.
19. Yasui, M.; Nonami, T.; Kurokawa, T.; Nakao, A.; Harada, A.; Hashimoto, S.; Kajikawa, M.; Hiraoka, E.; Takagi, H. Effects of hepatic arterial infusion chemotherapy on unresectable or recurrent hepatocellular carcinoma. Cancer Chemother. Pharmacol. 1994, 33, S139-S141.
20. Tzoracoleftherakis, E.E.; Spiliotis, J.D.; Kyriakopoulou, T.; Kakkos, S.K. Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 1999, 46, 1122-1125.
21. Osuga, K.; Murakami, T.; Nakata, S.; Tomoda, K.; Nagano, H.; Monden, M.; Nakamura, H. Hepatic arterial infusion chemotherapy (HAIC)-Hepatocellular carcinoma (in Japanese). Gan To Kagaku Ryoho 2004, 31, 2114-2117.
22. Ando, K.; Hirai, K.; Kubo, Y. Intra-arterial administration of epirubicin in the treatment of nonresectable hepatocellular carcinoma. Cancer Chemother. Pharmacol. 1987, 19, 183-188.
23. Yoshikawa, M.; Saisho, H.; Ebara, M.; Iijima, T.; Iwama, S.; Endo, F.; Kimura, M. Shimamura, Y.; Suzuki, Y.; Nakano, T. A randomized trial of intrahepatic arterial infusion of 4'-epidoxorubicin with Lipiodol versus 4'-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother. Pharmacol. 1994, 33, S149-S152.
24. Hwang, J.Y.; Jang, B.K.; Kwon, K.M.; Chung, W.J.; Park, K.S.; Cho, K.B.; Hwang, J.S.; Ahn, S.H.; Kim, G.C.; Kim, Y.H.; et al. Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C (in Korean). Korean J. Gastroenterol. 2005, 45, 118-124.
25. Ikeda, M.; Okusaka, T.; Ueno, H.; Morizane, C.; Iwasa, S.; Hagihara, A.; Kojima, Y. Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. Oncology 2007, 72, 188-193.
26. Tanaka, T.; Ikeda, M.; Okusaka, T.; Ueno, H.; Morizane, C.; Ogura, T.; Hagihara, A.; Iwasa, S. A. phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization. Cancer Chemother. Pharmacol. 2008, 61, 683-688.
27. Ikushima, I.; Higashi, S.; Seguchi, K.; Ishii, A.; Ota, Y.; Shima, M.; Kanemaru, M.; Hidaka, Y. Transarterial infusion chemotherapy with epirubicin in water-in-oil-in-water emulsion for recurrent hepatocellular carcinoma in the residual liver after hepatectomy. Eur. J. Radiol. 2009, 69, 114-119.
28. Sahara, S.; Kawai, N.; Sato, M.; Minamiguchi, H.; Nakai, M.; Takasaka, I.; Nakata, K.; Ikoma, A.; Sawa, N.; Sonomura, T.; et al. Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma. Jpn. J. Radiol. 2010, 28, 362-368.
29. Yamanaka, K.; Hatano, E.; Narita, M.; Taura, K.; Yasuchika, K.; Nitta, T.; Arizono, S.; Isoda, H.; Shibata, T.; Ikai, I.; et al. Comparative study of cisplatin and epirubicin in transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol. Res. 2011, 41, 303-309.
30. Kim, H.Y.; Kim, J.D.; Bae, S.H.; Park, J.Y.; Han, K.H.; Woo, H.Y.; Choi, J.Y.; Yoon, S.K.; Jang, B.K.; Hwang, J.S.; et al.; Korean Liver Cancer Study Group. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J. Hepatol. 2010, 16, 355-361.
31. Mäkelä, J.T.; Kantola, R.; Kairaluoma, M.I. Superselective intra-arterial chemotherapy with mitomycin C for hepatocellular carcinoma. Surg. Oncol. 1993, 2, 99-104.
32. Lu, W.; Li, Y.H.; Yu, Z.J.; He, X.F.; Chen, Y.; Zhao, J.B.; Zhu, Z.Y. A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. Hepatogastroenterology 2007, 54, 1499-1502.
33. Doci, R.; Bignami, P.; Bozzetti, F.; Bonfanti, G.; Audisio, R.; Colombo, M.; Gennari, L. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 1988, 61, 1983-1987.
34. Iwamiya, T.; Sawada, S.; Ohta, Y. Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother. Pharmacol. 1994, 33, S134-S138.
35. Patt, Y.Z.; Hassan, M.M.; Lozano, R.D.; Brown, T.D.; Vauthey, J.N.; Curley, S.A.; Ellis, L.M. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alpha-2b for treatment of hepatocellular carcinoma. J. Clin. Oncol. 2003, 21, 421-427.
36. Llovet, J.M.; Sala, M.; Castells, L.; Suarez, Y.; Vilana, R.; Bianchi, L.; Ayuso, C.; Vargas, V.; Rodés, J.; Bruix, J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000, 31, 54-58.
37. Lai, Y.C.; Shih, C.Y.; Jeng, C.M.; Yang, S.S.; Hu, J.T.; Sung, Y.C.; Liu, H.T.; Hou, S.M.; Wu, C.H.; Chen, T.K. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J. Gastroenterol. 2003, 9, 2666-2670.
38. Sakon, M.; Nagano, H.; Dono, K.; Nakamori, S.; Umeshita, K.; Yamada, A.; Kawata, S.; Imai, Y.; Iijima, S.; Monden, M. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002, 94, 435-442.
39. Obi, S.; Yoshida, H.; Toune, R.; Unuma, T.; Kanda, M.; Sato, S.; Tateishi, R.; Teratani, T.; Shiina, S.; Omata, M. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006, 106, 1990-1997.
40. Nagano, H.; Wada, H.; Kobayashi, S.; Marubashi, S.; Eguchi, H.; Tanemura, M.; Tomimaru, Y.; Osuga, K.; Umeshita, K.; Doki, Y.; et al. Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 2011, 80, 63-69.
41. Kondo, M.; Nagano, H.; Wada, H.; Damdinsuren, B.; Yamamoto, H.; Hiraoka, N.; Eguchi, H.; Miyamoto, A.; Yamamoto, T.; Ota, H.; et al. Combination of IFN-α and 5-fluorouracil induces apoptosis through IFN-α/β receptor in human hepatocellular cells. Clin. Cancer Res. 2005, 11, 1277-1286.
42. Kasai, K.; Ushio, A.; Kasai, Y.; Sawara, K.; Miyamoto, Y.; Oikawa, K.; Kuroda, H.; Takikawa, Y.; Suzuki, K. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. Int J. Clin. Oncol. 2011, 16, 221-229.
43. Yano, H.; Iemura, A.; Haramaki, M.; Ogasawara, S.; Takayama, A.; Akiba, J.; Kojiro, M. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999, 29, 1708-1717.
44. Kasai, K.; Kuroda, H.; Ushio, A.; Sawara, K.; Takikawa, Y.; Suzuki, K. Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion: Preliminary results. Hepatol. Res. 2009, 39, 117-125.
45. Enjoji, M.; Morizono, S.; Kotoh, K.; Kohjima, M.; Miyagi, Y.; Yoshimoto, T.; Nakamuta, M. Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. World J. Gastroenterol.2005,11, 5685-5687.
46. Ota, H.; Nagano, H.; Sakon, M.; Eguchi, H.; Kondo, M.; Yamamoto, T.; Nakamura, M.; Damdinsuren, B.; Wada, H.; Marubashi, S.; et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br. J. Cancer 2005, 93, 557-564.
47. Uka, K.; Aikata, H.; Takaki, S.; Miki, D.; Kawaoka, T.; Jeong, S.C.; Takahashi, S.; Toyota, N.; Ito, K.; Chayama, K. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J. Gastroenterol. 2007, 42, 845-853.
48. Kuroda, M.; Kobayashi, Y.; Urawa, N.; Yamamoto, M.; Mifuji, R.; Araki, J.; Tanaka, H.; Horiike, S.; Itani, T.; Furjita, N.; et al. Hepatic arterial infusion of 5-fluorouracil in combination withsubcutaneousinterferon-alphaforadvancedhepatocellularcarcinoma. Hepatogastroenterology 2007, 54, 518-521.
49. Katamura, Y.; Aikata, H.; Takaki, S.; Azakami, T.; Kawaoka, T.; Waki, K.; Hiramatsu, A.; Kawakami, Y.; Takahashi, S.; Kenjo, M.; et al. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J. Gastroenterol. 2009, 44, 492-502.
50. Scanlon, K.J.; Safirstein, R.L.; Thies, H.; Gross, R.B.; Waxman, S.; Guttenplan, J.B. Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res. 1983, 43, 4211-4215.
51. Ando, E.; Tanaka, M.; Yamashita, F.; Kuromatsu, R.; Yutani, S.; Fukumori, K.; Sumie, S.; Yano, Y.; Okuda, K.; Sata, M. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases. Cancer 2002, 95, 588-595.
52. Ueshima, K.; Kudo, M.; Takita, M.; Nagai, T.; Tatsumi, C.; Ueda, T.; Kitai, S.; Ishikawa, E.; Yada, N.; Inoue, T.; et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010, 78, 148-153.
53. Kim, N.Y.; Sun, J.M.; Kim, Y.J.; Lee, K.W.; Kim, J.H.; Bang, S.M.; Kim, J.W.; Jeong, S.H.; Lee, J.S. Cisplatin-based combination chemotherapy for advanced hepatocellular carcinoma: A single center experience before the Sorafenib Era. Cancer Res. Treat. 2010, 42, 203-209.
54. Park, J.Y.; Ahn, S.H.; Yoon, Y.J.; Kim, J.K.; Lee, H.W.; Lee do, Y.; Chon, C.Y.; Moon, Y.M.; Han, K.H. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007, 110, 129-137.
55. Woo, H.Y.; Bae, S.H.; Park, J.Y.; Han, K.H.; Chun, H.J.; Choi, B.G.; Im, H.U.; Choi, J.Y.; Yoon, S.K.; Cheong, J.Y.; et al.; Korean Liver Cancer Study Group. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2010, 65, 373-382.
56. Itamoto, T.; Nakahara, H.; Tashiro, H.; Haruta, N.; Asahara, T.; Naito, A.; Ito, K. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J. Surg. Oncol. 2002, 80, 143-148.
57. Lai, Y.C.; Shih, C.Y.; Jeng, C.M.; Yang, S.S.; Hu, J.T.; Sung, Y.C.; Liu, H.T.; Hou, S.M.; Wu, C.H.; Chen, T.K. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J. Gastroenterol. 2003, 9, 2666-2670.
58. Sumie, S.; Yamashita, F.; Ando, E.; Tanaka, M.; Yano, Y.; Fukumori, K.; Sata, M. Interventional radiology for advanced hepatocellular carcinoma: Comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. Am. J. Roentgenol. 2003, 181, 1327-1334.
59. Yamasaki, T.; Kimura, T.; Kurokawa, F.; Aoyama, K.; Ishikawa, T.; Tajima, K.; Yokoyama, Y.; Takami, T.; Omori, K.; Kawaguchi, K.; et al. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J. Gastroenterol. 2005, 40, 70-78.
60. Go, R.S.; Adjei, A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 1999, 17, 409-422.
61. Court, W.S.; Order, S.E.; Siegel, J.A.; Johnson, E.; DeNittis, A.S.; Principato, R.; Martz, K.; Zeiger, L.S. Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest. 2002, 20, 613-625.
62. Yoshikawa, M.; Ono, N.; Yodono, H.; Ichida, T.; Nakamura, H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol. Res. 2008, 38, 474-483.
63. Carr, B.I. Hepatic artery chemoembolization for advanced stage HCC: Experience of 650 patients. Hepatogastroenterology 2002, 49, 79-86.
64. Chung, Y.H.; Song, I.H.; Song, B.C.; Lee, G.C.; Koh, M.S.; Yoon, H.K.; Lee, Y.S.; Sung, K.B.; Suh, D.J. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000, 88, 1986-1991.
65. Murata, K.; Shiraki, K.; Kawakita, T.; Yamamoto, N.; Okano, H.; Nakamura, M.; Sakai, T.; Deguchi, M.; Ohmori, S.; Nakano, T. Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res. 2003, 23, 1719-1722.
66. Koizumi, Y.; Hirooka, M.; Uehara, T.; Kisaka, Y.; Uesugi, K.; Kumagi, T.; Abe, M.; Matsuura, B.; Hiasa, Y.; Onji, M. Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC. Hepatogastroenterology 2011, 58, 512-515.
67. Kim, B.K.; Park, J.Y.; Choi, H.J.; Kim do, Y.; Ahn, S.H.; Kim, J.K.; Lee do, Y.; Lee, K.H.; Han, K.H. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2011, 137, 659-667.
68. Nagamatsu, H.; Hiraki, M.; Mizukami, N.; Yoshida, H.; Iwamoto, H.; Sumie, S.; Torimura, T.; Sata, M. Intra-arterial therapy with cisplatin suspension in lipiodol and5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol. Ther. 2010, 32, 543-550.
69. Ikeda, M.; Maeda, S.; Shibata, J.; Muta, R.; Ashihara, H.; Tanaka, M.; Fujiyama, S.; Tomita, K. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004, 66, 24-31.
70. Ikeda, M.; Maeda, S.; Ashihara, H.; Nagahama, H.; Tanaka, M.; Sasaki, Y. Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma. J. Gastroenterol. 2010, 45, 60-67.
71. Okuda, K.; Tanaka, M.; Shibata, J.; Ando, E.; Ogata, T.; Kinoshita, H.; Eriguchi, N.; Aoyagi, S.; Tanikawa, K. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol. Rep. 1999, 6, 587-591.
72. Maeda, N.; Osuga, K.; Higashihara, H.; Tomoda, K.; Mikami, K.; Nakazawa, T.; Nakamura, H.; Tomiyama, N. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-lipiodol emulsion. Cardiovasc. Intervent. Radiol. 2011, 35, 82-89.
73. Kawamura, Y.; Ikeda, K.; Kumada, H. Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization using epirubicin (in Japanese). Gan To Kagaku Ryoho 2010, 37, 402-407.
74. Katamura, Y.; Aikata, H.; Hashimoto, Y.; Kimura, Y.; Kawaoka, T.; Takaki, S.; Waki, K.; Hiramatsu, A.; Kawakami, Y.; Takahashi, S.; et al. Pilot study of systemic combination therapy with S-1, an oral fluoropyrimidine, and cisplatin for hepatocellular carcinoma with extrahepatic metastases. Hepatogastroenterology 2010, 57, 1272-1278.
75. Konno, T.; Maeda, H.; Iwai, K.; Tashiro, S.; Maki, S.; Morinaga, T.; Mochinaga, M.; Hiraoka, T.; Yokoyama, I. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: A preliminary report. Eur. J. Cancer Clin. Oncol. 1983, 19, 1053-1065.
76. Tashiro, S.; Maeda, H. Clinical evaluation of arterial administration of SMANCS in oily contrast medium for liver cancer. Jpn. J. Med. 1985, 24, 79-80.
77. Okusaka, T.; Okada, S.; Ueno, H.; Ikeda, M.; Iwata, R.; Furukawa, H.; Takayasu, K.; Moriyama, N.; Sato, T.; et al. Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma. Oncology 2002, 62, 228-233.
78. Okusaka, T.; Kasugai, H.; Ishii, H.; Kudo, M.; Sata, M.; Tanaka, K.; Shioyama, Y.; Chayama, K.; Kumada, H.; Yoshikawa, M.; et al. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. Invest. New Drugs 2011, DOI: 10.1007/s10637-011-9776-4.
79. Maeda, M.; Uchida, U.A.; Sasaki, T. Liposoluble platinum (II) complexes with antitumor activity. Jpn. J. Cancer Res. 1986, 77, 523-525.
80. Kishimoto, S.; Noguchi, T.; Yamaoka, T.; Fukushima, S.; Takeuchi, Y. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly growing rat hepatic tumor after intra-hepatic arterial administration. Biol. Pharm. Bull. 2000, 23, 344-348.
81. Hanada, M.; Baba, A.; Tsutsumishita, Y.; Noguchi, T.; Yamaoka, T.; Chiba, N.; Nishikaku, F. Intra-arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother. Pharmacol. 2009, 64, 473-483.
82. Imai, Y.; Chikayama, T.; Nakazawa, M.; Watanabe, K.; Ando, S.; Mizuno, Y.; Yoshino, K.; Sugawara, K.; Hamaoka, K.; Fujimori, K.; et al. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J. Gastroenterol. 2011, DOI: 10.1007/s00535-011-0475-x.
83. Hanada, M.; Baba, A.; Tsutsumishita, Y.; Noguchi, T.; Yamaoka, T. Intra-arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci. 2009, 100, 189-194.
84. Okusaka, T.; Okada, S.; Nakanishi, T.; Fujiyama, S.; Kubo, Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest. New Drugs 2004, 22, 169-176.
85. Imai, N.; Ikeda, K.; Kawamura, Y.; Sezaki, H.; Hosaka, T.; Akuta, N.; Kobayashi, M.; Saitoh, S.; Suzuki, F.; Suzuki, Y.; et al. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Jpn. J. Clin. Oncol. 2011, doi:10.1093/jjco/hyr189.
86. Uyama, N.; Hatano, E.; Maetani, Y.; Isoda, H.; Shibata, T.; Taura, K.; Oe, S.; Naito, M.; Yasuchika, K.; Fujii, H.; et al. Efficacy and toxicity of transcatheter arterial chemoembolization with Cisplatin suspended in lipiodol for unresectable hepatocellular carcinoma (in Japanese). Gan To Kagaku Ryoho 2008, 35, 775-780.
87. Imai, N.; Ikeda, K.; Seko, Y.; Matsumoto, N.; Kawamura, Y.; Hosaka, T.; Kobayashi, M.; Saitoh, S.; Sezaki, H.; Akuta, N.; et al. Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure. Nihon Shokakibyo Gakkai Zasshi 2011, 108, 1872-1878.
88. Watanabe, S.; Nitta, N.; Ohta, S.; Sonoda, A.; Otani, H.; Tomozawa, Y.; Nitta-Seko, A.; Tsuchiya, K.; Tanka, T.; Takahashi, M.; Murata, K. Comparison of the anti-tumor effects of two platinum agents (miriplatin and fine-powder cisplatin). Cardiovasc. Intervent. Radiol. 2011, doi:10.1007/s00270-011-0172-4.
89. Wang, Z.; Zhou, J.; Fan, J.; Qiu, S.J.; Yu, Y.; Huang, X.W.; Sun, J.; Tan, C.J.; Dai, Z. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin. Investig. Drugs 2009, 18, 1595-1604.
90. Lombardi, L.; Morelli, F.; Cinieri, S.; Santini, D.; Silvestris, N.; Fazio, N.; Orlando, L.; Tonini, G.; Colucci, G.; Maiello, E. Adjuvant colon cancer chemotherapy: Where we are and where we'll go. Cancer Treat. Rev. 2010, 36, S34-S41.
91. Rathore, R.; Safran, H.; Soares, G.; Dubel, G.; McNulty, B.; Ahn, S.; Iannitti, D.; Kennedy, T. Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: A brown university oncology group study. Am. J. Clin. Oncol. 2010, 33, 43-46.
92. Breedis, C.; Young, G. The blood supply of neoplasms in the liver. Am. J. Pathol. 1954, 30, 969-977.
93. Okada, S. Chemotherapy in hepatocellular carcinoma. Hepatogastroenterology1998,45, 1259-1263.
94. Di Maio, M.; de Maio, E.; Perrone, F.; Pignata, S.; Daniele, B. Hepatocellular carcinoma: Systemic treatments. J. Clin. Gastroenterol. 2002, 35, S109-S114.
95. Aguayo, A.; Patt, Y.Z. Nonsurgical treatment of hepatocellular carcinoma. Semin. Oncol. 2001, 28, 503-513.
96. Eguchi, H.; Nagano, H.; Yamamoto, H.; Miyamoto, A.; Kondo, M.; Dono, K.; Nakamori, S.; Umeshita, K.; Sakon, M.; Monden, M. Augmentation of antitumor activity of 5-fluorouracil by IFN-α is associated with upregulation of p27Kip1 in human hepatocellular carcinoma cells. Clin. Cancer Res. 2000, 6, 2881-2890.
97. Nagano, H. Treatment of advanced hepatocellular carcinoma: Intraarterial infusion chemotherapy combined with interferon. Oncology 2010, 78, 142-147.
98. Jang, J.W.; Bae, S.H.; Choi, J.Y.; Oh, H.J.; Kim, M.S.; Lee, S.Y.; Kim, C.W.; Chang, U.I.; Nam, S.W.; Cha, S.B.; et al. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother. Pharmacol. 2007, 59, 9-15.
99. Kasugai, H.; Kojima, J.; Tatsuta, M.; Okuda, S.; Sasaki, Y.; Imaoka, S.; Fujita, M.; Ishiguro, S. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989, 97, 965-971.
100. Kurokawa, Y.; Matoba, R.; Nagano, H.; Sakon, M.; Takemasa, I.; Nakamori, S.; Dono, K.; Umeshita, K.; Ueno, N.; Ishii, S.; et al. Molecular prediction of response to 5-fluorouracil and IFN-α combination chemotherapy in advanced hepatocellular carcinoma. Clin. Cancer Res. 2004, 10, 6029-6038.
101. Nishikawa, H.; Inuzuka, T.; Takeda, H.; Nakajima, J.; Sakamoto, A.; Henmi, S.; Ishikawa, T.; Saito, S.; Kita, R.; Kimura, T.; et al. A case of advanced hepatocellular carcinoma with portal vein tumor thrombus refractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin. Case Rep. Oncol. 2011, 4, 327-335.
102. Kudo, M. Current status of molecularly targeted therapy for hepatocellular carcinoma: Clinical practice. Int. J. Clin. Oncol. 2010, 15, 242-255.
103. Ishizaki, M.; Kaibori, M.; Matsui, K.; Yanagimoto, Y.; Nakatake, R.; Kwon, A.H. The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus-A pilot study (in Japanese). Gan To Kagaku Ryoho 2010, 37, 2679-2682.
104. Yang, M.Y.; Jeong, S.W.; Kim, D.K.; Kim, S.G.; Jang, J.Y.; Kim, Y.S.; Lee, J.S.; Kim, B.S.; Kim, J.H.; Kim, Y.J.; et al. Treatment of hepatocellular carcinoma with portal vein thrombosis by sorafenib combined with hepatic arterial infusion chemotherapy. Gut Liver 2010, 4, 423-427.
105. Kemeny, N.E.; Schwartz, L.; Gönen, M.; Yopp, A.; Gultekin, D.; D'Angelica, M.I.; Fong, Y.; Haviland, D.; Gewirtz, A.N.; Allen, P.; et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: Does the addition of systemic bevacizumab improve results? Oncology 2011, 80, 153-159.